Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN20934 in Overweight or Obesity
NCT07594093Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing REGN20934 with Placebo (2 arms). Primary endpoints: Occurrence of Treatment Emergent Adverse Events at 16 weeks and Severity of Treatment Emergent Adverse Events at 16 weeks. Started Jun 2026; status: recruiting.
02
Drugs
REGN20934
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07594093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594093.